Glenn Nussdorf Sells 4,156 Shares of Organogenesis (NASDAQ:ORGO) Stock

Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf sold 4,156 shares of Organogenesis stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $3.50, for a total transaction of $14,546.00. Following the completion of the transaction, the director directly owned 354,339 shares of the company’s stock, valued at $1,240,186.50. This trade represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Organogenesis Stock Performance

Shares of NASDAQ ORGO traded down $0.25 during midday trading on Monday, hitting $4.00. The company’s stock had a trading volume of 1,648,527 shares, compared to its average volume of 1,276,991. The firm has a market cap of $507.43 million, a P/E ratio of -28.57 and a beta of 1.68. Organogenesis has a 1-year low of $2.61 and a 1-year high of $6.71. The firm’s fifty day moving average price is $4.48 and its 200-day moving average price is $4.19.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%.The company had revenue of $101.01 million for the quarter, compared to the consensus estimate of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. As a group, research analysts predict that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

ORGO has been the topic of a number of analyst reports. Cantor Fitzgerald increased their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Organogenesis in a research note on Wednesday, October 8th. Finally, BTIG Research reaffirmed a “buy” rating and set a $7.00 price target on shares of Organogenesis in a report on Friday, September 26th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Organogenesis has a consensus rating of “Hold” and an average price target of $7.33.

Hedge Funds Weigh In On Organogenesis

Large investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC increased its position in shares of Organogenesis by 10.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company’s stock worth $187,000 after acquiring an additional 4,239 shares in the last quarter. CWM LLC increased its position in shares of Organogenesis by 8.9% in the first quarter. CWM LLC now owns 63,894 shares of the company’s stock worth $276,000 after acquiring an additional 5,239 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in shares of Organogenesis in the third quarter worth approximately $25,000. Farther Finance Advisors LLC purchased a new position in shares of Organogenesis in the second quarter worth approximately $35,000. Finally, Intrepid Family Office LLC increased its position in shares of Organogenesis by 10.0% in the second quarter. Intrepid Family Office LLC now owns 110,000 shares of the company’s stock worth $403,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.